Cytokines Explained: The Signaling Molecules That Control Immunity

What Cytokines Are and How They Work

Cytokines are small, soluble glycoproteins typically ranging from 8 to 40 kilodaltons in molecular weight. They are produced by nearly every cell type in the body, though immune cells, particularly macrophages, dendritic cells, and T helper cells, are the most prolific producers. Unlike hormones, which are produced by dedicated glands and act on distant organs, cytokines are typically produced locally and act on nearby cells (paracrine signaling) or on the producing cell itself (autocrine signaling). Some cytokines also enter the bloodstream and act systemically (endocrine signaling), producing body-wide effects such as fever, acute phase protein production, and metabolic changes.

Cytokines exert their effects by binding to specific receptors on the surface of target cells. Each cytokine has a dedicated receptor, and cells express different combinations of cytokine receptors depending on their type and activation state. When a cytokine binds its receptor, it triggers an intracellular signaling cascade, most commonly through the JAK-STAT pathway, that ultimately alters gene expression in the target cell. The changes in gene expression can cause the cell to proliferate, differentiate, migrate, secrete other cytokines, or undergo apoptosis.

Several key properties distinguish cytokine signaling from simpler communication systems. Cytokines are pleiotropic, meaning a single cytokine can have different effects on different cell types. IL-4, for example, promotes B cell class switching to IgE, stimulates Th2 differentiation, and activates macrophages toward an anti-inflammatory phenotype. Cytokines are also redundant, meaning multiple cytokines can produce similar effects, providing backup in case one signaling pathway is compromised. And cytokines can be synergistic or antagonistic, amplifying or counteracting each other's effects. This complexity allows the immune system to generate nuanced, context-dependent responses rather than simple on/off switches.

Interleukins: Communication Between Leukocytes

Interleukins (ILs) are the largest and most diverse family of cytokines, with over 40 members identified as of 2026. The name, meaning "between leukocytes," reflects the original observation that these molecules mediate communication among white blood cells, though many interleukins also act on non-immune cells. Several interleukins play central roles in immune regulation that are worth understanding in detail.

IL-1 (specifically IL-1 beta) is one of the earliest cytokines released during an infection, primarily by activated macrophages and dendritic cells. It is a potent pro-inflammatory cytokine that induces fever by acting on the hypothalamus, stimulates the liver to produce acute phase proteins such as C-reactive protein, and activates endothelial cells to express adhesion molecules that recruit neutrophils from the bloodstream. IL-1 production is controlled by the inflammasome, an intracellular protein complex that assembles in response to danger signals and activates the enzyme caspase-1, which cleaves the inactive pro-IL-1 beta precursor into its active form. Dysregulated inflammasome activation and excessive IL-1 production cause a group of diseases called autoinflammatory syndromes, including familial Mediterranean fever and cryopyrin-associated periodic syndromes. The IL-1 receptor antagonist anakinra is used to treat these conditions.

IL-2 is the primary growth factor for T cells. Originally called T cell growth factor, IL-2 is produced mainly by activated CD4+ helper T cells and drives the clonal expansion of T cells after antigen recognition. It also promotes the development and maintenance of regulatory T cells, creating a feedback loop in which the same cytokine that amplifies immune responses also generates the cells that suppress them. This dual role means that IL-2 deficiency leads to autoimmunity rather than immunodeficiency, because the loss of Treg function is more consequential than the reduction in effector T cell expansion. Low-dose IL-2 therapy is being explored as a treatment for autoimmune diseases, because low concentrations preferentially expand Tregs (which express high levels of the high-affinity IL-2 receptor) without significantly activating effector T cells.

IL-6 is a pleiotropic cytokine with roles in both inflammation and adaptive immunity. Produced by macrophages, dendritic cells, T cells, and many non-immune cell types, IL-6 stimulates the liver to produce acute phase proteins, promotes B cell differentiation into plasma cells, and drives the differentiation of naive T cells into Th17 cells. IL-6 is also a key mediator of chronic inflammatory diseases. Elevated IL-6 levels are found in rheumatoid arthritis, Castleman disease, and the cytokine release syndrome that can accompany CAR-T cell therapy. The anti-IL-6 receptor antibody tocilizumab (Actemra) was originally developed for rheumatoid arthritis and was later repurposed for severe COVID-19, where excessive IL-6 signaling contributed to lung damage.

IL-10 is the most important anti-inflammatory cytokine, produced mainly by regulatory T cells, regulatory B cells, and alternatively activated macrophages. It suppresses the production of pro-inflammatory cytokines by macrophages and dendritic cells, inhibits antigen presentation, and limits tissue damage during immune responses. IL-10 deficient mice develop severe spontaneous colitis, demonstrating that IL-10 is essential for maintaining intestinal immune homeostasis. In humans, mutations in IL-10 or its receptor cause very early onset inflammatory bowel disease, typically presenting in the first year of life.

Interferons: The Antiviral Defense System

Interferons (IFNs) were discovered in 1957 as factors that "interfered" with viral replication, and they remain among the best-studied cytokines. They are divided into three types based on their receptor usage and biological functions.

Type I interferons, including IFN-alpha (produced mainly by plasmacytoid dendritic cells) and IFN-beta (produced by most cell types), are the primary cytokines of the innate antiviral response. When a cell detects viral nucleic acids through pattern recognition receptors such as RIG-I, MDA5, or TLR3/7/8, it produces type I interferons that act on neighboring cells to induce an "antiviral state." This state involves the upregulation of hundreds of interferon-stimulated genes (ISGs) whose protein products inhibit viral replication through diverse mechanisms: degrading viral RNA, blocking viral protein synthesis, inhibiting viral assembly, and preventing viral release. Type I interferons also activate NK cells, enhance MHC class I expression (making infected cells more visible to cytotoxic T cells), and promote dendritic cell maturation.

Type II interferon consists of a single member, IFN-gamma, produced primarily by T cells and NK cells. IFN-gamma is the signature cytokine of Th1 immune responses and the most potent activator of macrophages. When macrophages receive IFN-gamma signals, they dramatically upregulate their antimicrobial mechanisms, including reactive oxygen and nitrogen species production, phagolysosome acidification, and antigen presentation. IFN-gamma is essential for defense against intracellular bacteria such as Mycobacterium tuberculosis, Listeria monocytogenes, and Salmonella. People with inherited defects in the IFN-gamma receptor are highly susceptible to mycobacterial infections, a condition called Mendelian susceptibility to mycobacterial disease (MSMD).

Type III interferons (IFN-lambda) were discovered more recently and act primarily at mucosal surfaces, particularly the respiratory and gastrointestinal epithelium. Their receptor is expressed mainly on epithelial cells, meaning IFN-lambda provides localized antiviral defense at the body's barrier surfaces without triggering the systemic inflammation that type I interferons can cause. This targeted action has made IFN-lambda an area of interest for developing antiviral therapies with fewer side effects than IFN-alpha-based treatments.

Chemokines: The Immune System's GPS

Chemokines are a family of approximately 50 small cytokines (8 to 12 kDa) whose primary function is directing cell migration, a process called chemotaxis. They are divided into four subfamilies based on the arrangement of conserved cysteine residues near the N-terminus: CC chemokines (with two adjacent cysteines), CXC chemokines (with one amino acid between the cysteines), CX3C chemokines, and C chemokines. Each chemokine binds to one or more G protein-coupled receptors (GPCRs) on the surface of target cells, and cells follow chemokine concentration gradients from low to high concentration, migrating toward the source of chemokine production.

During an infection, damaged tissue and activated macrophages release inflammatory chemokines including CXCL8 (IL-8), CCL2 (MCP-1), and CCL3 (MIP-1 alpha). CXCL8 is the most potent neutrophil attractant, drawing neutrophils from the bloodstream into infected tissue. CCL2 recruits monocytes, which differentiate into macrophages at the site of infection. CCL3 and CCL4 recruit NK cells and additional macrophages. This ordered recruitment ensures that the right cells arrive at the right place in the right sequence.

Homeostatic chemokines operate constitutively, without infection, to organize immune cell trafficking through lymphoid tissues. CCL19 and CCL21 guide T cells and dendritic cells into the T cell zones of lymph nodes, while CXCL13 guides B cells into follicles. This spatial organization is essential for efficient antigen presentation: dendritic cells carrying pathogen fragments from peripheral tissues follow CCL21 gradients into lymph node T zones, where they are most likely to encounter the rare T cells that recognize their specific antigen. Without this chemokine-directed organization, the probability of a dendritic cell finding its matching T cell would be vanishingly small.

Chemokine receptors also serve as entry points for pathogens. HIV uses CCR5 and CXCR4 as co-receptors to infect CD4+ T cells, and a naturally occurring 32-base-pair deletion in the CCR5 gene (CCR5-delta32), found in approximately 10 percent of Northern Europeans, confers resistance to HIV infection. The "Berlin patient" (Timothy Ray Brown), the first person cured of HIV, received a bone marrow transplant from a donor homozygous for CCR5-delta32, and the transplanted immune system was resistant to HIV re-infection.

Tumor Necrosis Factor and Its Family

Tumor necrosis factor alpha (TNF-alpha) is one of the most important pro-inflammatory cytokines, named for its ability to kill tumor cells in early experiments. It is produced primarily by activated macrophages, T cells, and NK cells, and it plays a central role in both innate immunity and inflammatory disease. TNF-alpha activates endothelial cells, promotes neutrophil adhesion and migration, stimulates macrophage antimicrobial activity, and induces fever. At high systemic concentrations, TNF-alpha can cause septic shock, a life-threatening condition characterized by vasodilation, increased vascular permeability, disseminated intravascular coagulation, and multi-organ failure.

TNF-alpha signals through two receptors, TNFR1 (expressed on nearly all cell types) and TNFR2 (expressed mainly on immune and endothelial cells). TNFR1 can trigger both pro-inflammatory signaling (through NF-kB activation) and apoptosis (through caspase activation), with the outcome depending on the cellular context. This dual signaling capacity makes TNF-alpha both a defender against infection and a potential driver of tissue damage.

The TNF superfamily includes approximately 20 related cytokines with diverse functions. Lymphotoxin-alpha (LT-alpha, also called TNF-beta) is essential for lymph node development. BAFF (B cell activating factor) and APRIL promote B cell survival and are therapeutic targets in autoimmune diseases. FasL (Fas ligand) triggers apoptosis in cells expressing the Fas receptor, contributing to immune homeostasis and cytotoxic T cell killing. TRAIL (TNF-related apoptosis-inducing ligand) selectively kills tumor cells while sparing most normal cells, making it an area of active cancer therapy research.

Cytokine Storms and Dysregulation

A cytokine storm, more precisely called hypercytokinemia or cytokine release syndrome (CRS), occurs when the immune system produces a massive, uncontrolled burst of pro-inflammatory cytokines that causes more damage than the infection itself. Rather than a controlled, localized immune response, the cytokine storm produces systemic inflammation that can damage multiple organs, increase vascular permeability leading to edema and hypotension, trigger disseminated intravascular coagulation, and ultimately cause organ failure and death.

The COVID-19 pandemic brought cytokine storms to widespread public attention. In severe COVID-19, SARS-CoV-2 infection triggered excessive production of IL-6, IL-1 beta, TNF-alpha, and other pro-inflammatory cytokines, leading to acute respiratory distress syndrome (ARDS) and multi-organ failure. The recognition that immune-mediated damage, not direct viral cytotoxicity, was the primary cause of death in severe cases shifted treatment strategies toward immunomodulation. Dexamethasone (a corticosteroid that broadly suppresses cytokine production) reduced mortality in hospitalized COVID-19 patients by roughly one-third, and IL-6 receptor blockade with tocilizumab provided additional benefit in critically ill patients.

Cytokine release syndrome is also a recognized complication of CAR-T cell therapy. When engineered T cells encounter and kill large numbers of tumor cells simultaneously, they release enormous quantities of IFN-gamma, which activates macrophages to produce IL-6, IL-1, and IL-10 in a positive feedback loop. Symptoms range from fever and fatigue in mild cases to life-threatening hypotension, capillary leak, and organ failure in severe cases. The anti-IL-6 receptor antibody tocilizumab was specifically approved for CAR-T-associated CRS, and its availability has made CAR-T therapy substantially safer.

Chronic cytokine dysregulation underlies many diseases that are not traditionally considered immunological. Elevated TNF-alpha drives joint destruction in rheumatoid arthritis. Excess IL-17 causes the keratinocyte hyperproliferation of psoriasis. Persistent low-grade elevation of IL-6 and TNF-alpha is associated with obesity, type 2 diabetes, atherosclerosis, and depression. Anti-cytokine therapies, including TNF inhibitors (infliximab, adalimumab, etanercept), IL-17 inhibitors (secukinumab), and IL-23 inhibitors (guselkumab), have become some of the most commercially successful drugs in pharmaceutical history, collectively generating over $60 billion in annual sales globally.